


Prostate Cancer Markers




Prostate cancer is the fourth most common cancer in both sexes combined and the second most common cancer in men. An estimated 1.1 million men worldwide were diagnosed with prostate cancer in 2012, accounting for 15% of the cancers diagnosed in men, with almost 70% of the cases (759k occurring in more developed regions). Prostate cancer incidence varies more than 25-fold worldwide. With an estimated 307,000 deaths in 2012, prostate cancer is the fifth leading cause of death from cancer in men (6.6% of the total men deaths). there is less variation in mortality rates worldwide (ten-fold from about 3 to 30 per 100,000).


GLOBOCAN database




FFPE human cervical ca stained with anti-c-Myc [MYC275+909]




FFPE human prostate ca stained with anti-CK5/6 [D5/16B4]




FFPE human prostate ca stained with anti-CK HMW [34BE12]



FFPE human prostate carcinoma stained with anti-IMP3 Polyclonal



FFPE human high-grade prostate ca stained with anti-NKX3.1 [EP356]



FFPE human prostate ca stained anti-p504S [13H4]

Prostate Cancer Markers

Name	Cat. No.	Application
AR [EP120]	RM0004	Used to identify prostate carcinoma
AR [SP107]	RM0218	
c-Myc [EP121]	RM0070	Overexpression implicated in the development and progression of prostate cancer
c-Myc [MYC275+909]	MC0134	
COX2 [EP293]	RM0362	Increased expression significantly associated with biochemical failure, distant metastasis of high-risk prostate cancer
COX2 [SP21]	RM0200	
CK5 [EP42]	RM0083	Useful for assessment of problematic prostate specimens
CK5/6 [D5/16B4]	MC0327	
CK6 [EP67]	RM0084	
CK6 [LHK6]	MC0750	
CK7 [EP16]	RM0085	Used to identify the organ origin of adenocarcinomas when combined with CK20; and differentiate benign prostate tumor (+) vs prostate cancer (-)
CK7 [OV-TL12/30]	MC0754	
CK HMW [34BE12]	MC0328	Reacts with benign small-acinar lesions of the prostate
ERG [EP111]	RM0094	Frequently overexpressed in prostate cancer
IMP3/KOC [EP286]	RM0344	Associated with metastasis and prostate cancer specific survival.
IMP3/KOC Polyclonal	RC0308	Enhanced expression in prostate cancer than normal prostate
MUC18/CD146 [EP54]	RM0026	Enforced expression increases prostate tumorigenesis in vivo and may affect the process by increasing proliferation, and augmenting the angiogenic ability of prostate cancer cells
MUC18/CD146 [OJ79c]	MC0862	
NKX3.1 [EP356]	RM0386	Combined with ERG, it may represent a superior combination to aid in identifying tumors of prostatic origin
NKX3.1 Polyclonal	RC0324	
p40 [MD6R]	RM0260	Might be more specific basal cell marker for the early stages of prostate cancer. May help indicate the prostatic intraepithelial neoplasia (PIN)
p40 Polyclonal	RC3114	
p504S (AMACR) [13H4]	RM0215	Usually found in prostatic adenocarcinoma but not in benign prostatic tissue by premalignant lesions of prostate
p63 [4A4]	MC0221	A standard marker for basal cells of the prostate gland
p63 [TP63/11]	MC0906	
PAP [EP53]	RM0167	PAP is no longer used to screen for or stage prostate cancer. In most instances, serum prostate specific antigen (PSA) is used instead
PD-L1 [MD21R]	RM0324	Expression linked to biochemical recurrence likely associated with clinical outcomes
PSA [A67-B/E3]	MC0925	Elevated serum level is an important marker for benign prostatic hyperplasia, prostatitis, and prostate cancer
PSA [ERPR-8]	MC0240	
PSA [EP109]	RM0166	

Medaysis

Prostate Cancer Markers

Name	Cat. No.	Application
PSAP [PASE/4LJ]	MC0354	May be helpful in pinpointing the site of origin in metastatic carcinoma of the prostate and is considered a more sensitive but less sensitive marker than PSA
PSMA [EP192]	RM0168	Expression correlates with the progression of prostate cancer with highest levels expressed in hormonerefractory and metastatic disease
PTEN [6H2.1]	MC0356	A reduction of PTEN expression in advanced prostate cancer
SOX2 [EP103]	RM0179	Boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis
Vimentin [EP21]	RM0195	Promotes tumor cell invasiveness and the targeting of vimentin/C-src may be a promising strategy for preventing or blocking prostate cancer metastasis
Vimentin [LN-6]	MC0965	
Vimentin [V9]	MC0268	

Research Use Only